Immuno Cure Biotech

Executive Summary

Immuno Cure Biotech is a Hong Kong-based preclinical biotechnology company dedicated to developing novel immunotherapies and vaccines for oncology and infectious diseases. Founded in 2017, the company leverages immune modulation to elicit targeted anti-tumor or protective immune responses. Its pipeline includes therapeutic cancer vaccines and immunomodulatory agents, though no specific candidates or clinical timelines have been disclosed publicly. Given its early stage, the company represents a high-risk, high-reward opportunity in the competitive immunotherapy landscape. With a small team and private status, progress is contingent on successful preclinical validation and subsequent fundraising or partnerships to advance into clinical trials.

Upcoming Catalysts (preview)

• TBDPreclinical proof-of-concept data for lead candidate20% success
• TBDIND filing for first therapeutic vaccine15% success
• TBDStrategic partnership or licensing deal25% success